File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Interim report on a phase I/IIa, double-blind, randomized, placebo-controlled trial of a novel antiviral agent, LB80380 in Chinese patients with chronic hepatitis B infection

TitleInterim report on a phase I/IIa, double-blind, randomized, placebo-controlled trial of a novel antiviral agent, LB80380 in Chinese patients with chronic hepatitis B infection
Authors
Issue Date2004
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
Citation
The 39th Annual Meeting of the European Association for the Study of the Liver, Berlin, Germany, 14-18 April 2004. In Journal of Hepatology, 2004, v. 40 n. S1, p. 133 Abstract no. 450 How to Cite?
AbstractTo investigate the safety and antiviral activity of LB80380, a novel guanosine analogue, in HBeAg-positive HBV patients, 28 patients in 4 cohorts (7 per group with 6:1 ratio of LB80380: placebo) were given escalating doses with 30mg, 60mg, 120mg and 240mg daily for 4 weeks. Patients were monitored till week 16. The median age and male:female ratio were 27.5 years and 20:8 respectively. The median follow-up was 8.9 weeks. HBV DNA reductions are depicted in the figure. HBV DNA reduction was greater with 60mg dose and above. HBV DNA returned to the pretreatment levels at a slower rate with higher doses. No serious adverse events were observed. In conclusion, four-week treatment of LB80380 was safe and associated with a reduction of HBV DNA levels greater than those observed with lamivudine and adefovir.
Persistent Identifierhttp://hdl.handle.net/10722/101997
ISSN
2014 Impact Factor: 11.336
2014 SCImago Journal Rankings: 3.477

 

DC FieldValueLanguage
dc.contributor.authorYuen, RMFen_HK
dc.contributor.authorKim, Jen_HK
dc.contributor.authorWong, DKHen_HK
dc.contributor.authorNgai, WSen_HK
dc.contributor.authorYuen, JCHen_HK
dc.contributor.authorLai, CLen_HK
dc.date.accessioned2010-09-25T20:12:56Z-
dc.date.available2010-09-25T20:12:56Z-
dc.date.issued2004en_HK
dc.identifier.citationThe 39th Annual Meeting of the European Association for the Study of the Liver, Berlin, Germany, 14-18 April 2004. In Journal of Hepatology, 2004, v. 40 n. S1, p. 133 Abstract no. 450en_HK
dc.identifier.issn0168-8278-
dc.identifier.urihttp://hdl.handle.net/10722/101997-
dc.description.abstractTo investigate the safety and antiviral activity of LB80380, a novel guanosine analogue, in HBeAg-positive HBV patients, 28 patients in 4 cohorts (7 per group with 6:1 ratio of LB80380: placebo) were given escalating doses with 30mg, 60mg, 120mg and 240mg daily for 4 weeks. Patients were monitored till week 16. The median age and male:female ratio were 27.5 years and 20:8 respectively. The median follow-up was 8.9 weeks. HBV DNA reductions are depicted in the figure. HBV DNA reduction was greater with 60mg dose and above. HBV DNA returned to the pretreatment levels at a slower rate with higher doses. No serious adverse events were observed. In conclusion, four-week treatment of LB80380 was safe and associated with a reduction of HBV DNA levels greater than those observed with lamivudine and adefovir.-
dc.languageengen_HK
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep-
dc.relation.ispartofJournal of Hepatologyen_HK
dc.titleInterim report on a phase I/IIa, double-blind, randomized, placebo-controlled trial of a novel antiviral agent, LB80380 in Chinese patients with chronic hepatitis B infectionen_HK
dc.typeConference_Paperen_HK
dc.identifier.emailYuen, RMF: mfyuen@hkucc.hku.hken_HK
dc.identifier.emailWong, DKH: danywong@hku.hken_HK
dc.identifier.emailNgai, WS: vinngai@HKUCC.hku.hken_HK
dc.identifier.emailYuen, JCH: jchyuen@HKUCC.hku.hken_HK
dc.identifier.emailLai, CL: hrmelcl@hku.hken_HK
dc.identifier.authorityYuen, RMF=rp00479en_HK
dc.identifier.authorityWong, DKH=rp00492en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/S0168-8278(04)90450-3-
dc.identifier.hkuros105373en_HK
dc.identifier.hkuros130911-
dc.identifier.volume40en_HK
dc.identifier.issueS1en_HK
dc.identifier.spage133en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats